Aurigene Oncology, a Dr. Reddy’s subsidiary, recently announced promising Phase 1 results for Ribrecabtagene autoleucel (DRL-1801), India’s first novel autologous CAR-T cell therapy for multiple myeloma.
The study, which included 8 heavily pre-treated patients, found 100% clinical response, with 62.5% achieving stringent complete response. The drug’s safety profile was positive with no high-grade events of CRS or neurotoxicity. The DCGI has approved Phase 2 trials based on the promising results.
Dr. Murali Ramachandra, CEO, Aurigene Oncology Limited, stated, “The results from the trial in heavily pre-treated relapsed refractory myeloma patients are very exciting for us in India. We are thrilled with the data, as the drug could be transformative for Indian patients with myeloma.”
